ProT-096 designed to address critical gaps in immune recovery for patients with refractory hematologic malignancies through a ...

Most people do not rush to a doctor for urinary discomfort. A little burning sensation, frequent bathroom visits at night, or ...

A new drug for pancreatic cancer, one of the deadliest cancers, saw patients live almost double the time compared to those ...

Moby summary of Cellectar Biosciences, Inc.'s Q1 2026 earnings call ...

The current prior authorization (PA) process is an administrative failure. Beyond the excessive time and paperwork required, ...

Iopofosine I-131 achieved an overall response rate of 83.6% and a major response rate of 61.8% in patients with relapsed or ...

Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to ...

The bacteria that cause tuberculosis can survive for months in damp, poorly ventilated spaces that receive little to no ...

Recently, ACROBiosystems successfully held its Innovation Day at Superlab Suisse Zürich Schlieren in Zurich, Switzerland, a ...

Building on feedback and experience from prior models, LEAD aims to reduce barriers to success for both new and experienced ...

The American criminal justice system is notoriously plagued with racial and gender bias, crippling caseloads and asymmetrical ...

Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen ...